Regenxbio (RGNX) Misses Q1 EPS by 38c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts RGNX Hot Sheet
Join SI Premium – FREE
Regenxbio (NASDAQ: RGNX) reported Q1 EPS of ($1.72), $0.38 worse than the analyst estimate of ($1.34). Revenue for the quarter came in at $6.39 million versus the consensus estimate of $25.8 million.
For earnings history and earnings-related data on Regenxbio (RGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Grainger (GWW) Tops Q3 EPS by 87c ; Offers Guidance
- ADP Employment Change (Oct) 86K vs 67K Expected
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
